- sterile injectable controlled release composition, comprising: at least one antipsychotic drug is risperidone and / or 9-OH-risperidone in any combination thereof at least one biocompatible polymer is based on glycolic and lactic acid carboxy-terminal protected copolymer has a monomer ratio of lactic acid to glycolic acid in the range of 50:50 to 75:25, and mass ratio of drug / polymer between 15 and 40% expressed as the weight percent of drug to polymer plus drug at least one water-miscible solvent with dipole moment D range 3.9 to 43, wherein said solvent is DMSO (dimethyl sulfoxide), the biocompatible polymer has an intrinsic inherent viscosity in the range of 0.16 to 0, 60 dl / g, measured in chloroform at 25 ° C and a concentration of 0.1% and the concentration of biocompatible polymer is in the range 25% -50% in weight percent polymer based on the total polymer solution the viscosity of the solution comprising the polymer and the solvent is between 0.5 and 7.0 Pa.s and the particle size distribution of the drug is as follows: - less than 10% of particles smaller than 10 microns - less than 10% of particles greater than 225 microns - a value D0.5 in the range 60-130 microns.- Composición estéril inyectable de liberación controlada , que comprende: al menos, un fármaco antipsicótico que es risperidona y/o 9-OH-risperidona en cualquier combinación de los mismos al menos un polímero biocompatible que es un copolímero basado en ácido glicólico y láctico con grupos carboxílicos terminales protegidos que posee una relación de monómero de ácido láctico a ácido glicólico en el rango de 50:50 a 75:25, y una relación en masa fármaco/polímero entre el 15 y el 40% expresado como el porcentaje del peso del fármaco con respecto al fármaco más el polímero al menos un disolvente miscible en agua con un momento dipolar en el rango de 3,9-43 D, caracterizado porque dicho disolvente es DMSO (dimetilsulfóxido), el polímero biocompatible posee una viscosidad inherente intrínseca
